Brought to you by 
Genzyme's tender offer for Bioenvision
17 Jul 2007
Executive Summary
In an effort to strengthen its oncology business, Genzyme has agreed to acquire all outstanding common shares of Bioenvision (cancer therapies) for $5.60 each (a 36% premium) and all outstanding Series A convertible preferred shares for $11.20; total transaction value would be $345mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme's tender offer for Bioenvision
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice